Cite

HARVARD Citation

    Xiang, M. et al. (2021). Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial. Oncologist. pp. e2130-e2135. [Online]. 
  
Back to record